Wednesday, September 21, 2016

Dorzolamide 20 mg / ml Eye Drops, Solution





1. Name Of The Medicinal Product



Dorzolamide 20 mg/ml Eye Drops, Solution


2. Qualitative And Quantitative Composition



Active substance: One ml contains 20 mg dorzolamide (as 22.3 mg of dorzolamide hydrochloride)



Excipient: 0.08 mg benzalkonium chloride/ml



For a full list of excipients, see section 6.1.



3. Pharmaceutical Form



Eye drops, solution



Isotonic, buffered, slightly viscous, aqueous solution.



4. Clinical Particulars



4.1 Therapeutic Indications



Dorzolamide is indicated:



• as adjunctive therapy to beta-blockers,



• as monotherapy in patients unresponsive to beta-blockers or in whom beta-blockers are contraindicated,in the treatment of elevated intra-ocular pressure in:



• ocular hypertension,



• open-angle glaucoma,



• pseudo-exfoliative glaucoma.



4.2 Posology And Method Of Administration



When used as monotherapy, the dose is one drop of dorzolamide in the conjunctival sac of the affected eye(s), three times daily.



When used as adjunctive therapy with an ophthalmic beta-blocker, the dose is one drop of dorzolamide in the conjunctival sac of the affected eye(s), two times daily.



When substituting dorzolamide for another ophthalmic anti-glaucoma agent, discontinue the other agent after proper dosing on one day, and start dorzolamide on the next day.



If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten minutes apart.



Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures.



Patients should also be instructed that ocular solutions, if handled improperly, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.



Patients should be informed of the correct handling of Dorzolamide eye drops solution.



Usage instructions



Please follow these instructions carefully when using Dorzolamide eye drops solution. It is recommended that you wash your hands before putting in your eye drops.



1. You must not use the bottle if the tamper-proof seal on the bottle neck is broken before you first use it.



2. To open the bottle unscrew the cap by turning it until the tamper-proof seal breaks.



3. Tilt your head back and pull your lower eyelid down slightly to form a pocket between your eyelid and your eye (Fig. 1).





4. Invert the container, and press gently as shown (Fig. 2) until a single drop as instructed by your doctor is dispensed into your eye. DO NOT TOUCH YOUR EYE OR EYELID WITH THE TIP OF THE CONTAINER.







5. Repeat steps 3 and 4 with the other eye if instructed to do so by your doctor.



6. Re-close the bottle by turning the cap firmly immediately after use and return the bottle to the original outer carton.



7. The dispenser tip is designed to provide a pre-measured drop; therefore, do not enlarge the hole of the dispenser tip.



Paediatric use



The experience in children is limited. Limited clinical data in paediatric patients with administration of dorzolamide three times a day are available. (For information regarding paediatric dosing see section 5.1).



4.3 Contraindications



Dorzolamide is contraindicated in patients who are hypersensitive to the active substance or to any of the excipients.



Dorzolamide has not been studied in patients with severe renal impairment (CrCl < 30 ml/min) or with hyperchloraemic acidosis. Because dorzolamide and its metabolites are excreted predominantly by the kidney, dorzolamide is therefore contraindicated in such patients.



4.4 Special Warnings And Precautions For Use



Dorzolamide has not been studied in patients with hepatic impairment and should therefore be used with caution in such patients.



The management of patients with acute angle-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents. Dorzolamide has not been studied in patients with acute angle-closure glaucoma.



Dorzolamide is a sulphonamide and although administered topically, is absorbed systemically. Therefore the same types of adverse reactions that are attributable to sulphonamides may occur with topical administration. If signs of serious reactions of hypersensitivity occur, discontinue the use of this preparation.



Therapy with oral carbonic anhydrase inhibitors has been associated with urolithiasis as a result of acid-base disturbances, especially in patients with a prior history of renal calculi. Although no acid-base disturbances have been observed with dorzolamide, urolithiasis has been reported infrequently. Because dorzolamide is a topical carbonic anhydrase inhibitor that is absorbed systemically, patients with a prior history of renal calculi may be at increased risk of urolithiasis while using dorzolamide.



If allergic reactions (e.g. conjunctivitis and eyelid reactions) are observed, discontinuation of treatment should be considered.



There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide. The concomitant administration of dorzolamide and oral carbonic anhydrase inhibitors is not recommended.



Corneal oedemas and irreversible corneal decompensations have been reported in patients with pre-existing chronic corneal defects and/or a history of intraocular surgery while using dorzolamide. Topical dorzolamide should be used with caution in such patients.



Choroidal detachment concomitant with ocular hypotony have been reported after filtration procedures with administration of aqueous suppressant therapies.



Dorzolamide contains the preservative benzalkonium chloride, which may cause eye irritation. Contact lenses should be removed prior to application and wait at least 15 minutes before reinsertion. Benzalkonium chloride is known to discolour soft contact lenses.



Paediatric patients:



Dorzolamide has not been studied in patients less than 36 weeks gestational age and less than one week of age. Patients with significant renal tubular immaturity should only receive dorzolamide after careful consideration of the risk benefit balance because of the possible risk of metabolic acidosis.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Specific drug interaction studies have not been performed with dorzolamide.



In clinical studies, dorzolamide was used concomitantly with the following medications without evidence of adverse interactions: timolol ophthalmic solution, betaxolol ophthalmic solution and systemic medications, including ACE-inhibitors, calcium-channel blockers, diuretics, non-steroidal anti-inflammatory drugs including acetylsalicylic acid, and hormones (e.g. oestrogen, insulin, thyroxine).



Association between dorzolamide and miotics and adrenergic agonists has not been fully evaluated during glaucoma therapy.



Dorzolamide is a carbonic anhydrase inhibitor and, although administered topically, it is also absorbed into the systemic circulation. In clinical studies, no acid-base disturbances have been observed in connection with dorzolamide use. However, such effects have been reported with oral carbonic anhydrase inhibitors, and in some cases they have resulted in medicine interactions (e.g. toxic reactions in patients receiving high doses of salicylates). The potential for such interactions should therefore be considered in association with dorzolamide therapy.



4.6 Pregnancy And Lactation



There are no adequate data from the use of dorzolamide in pregnant women. Studies in rabbits have shown teratogenic effect at maternotoxic doses (see section 5.3).



Dorzolamide should not be used during pregnancy.



Lactation: There are no data showing whether the drug is excreted in human milk. Dorzolamide should not be used during lactation. In lactating rats, decreases in the body weight gain of offspring were observed.



4.7 Effects On Ability To Drive And Use Machines



Dorzolamide has minor or moderate influence on the ability to drive and use machines.



Possible side effects such as dizziness and visual disturbances may affect the ability to drive and use machines (see also section 4.8).



4.8 Undesirable Effects



Dorzolamide containing eye drops was evaluated in more than 1400 individuals in controlled and uncontrolled clinical studies. In long term studies of 1108 patients treated with Dorzolamide containing eye drops as monotherapy or as adjunctive therapy with an ophthalmic beta-blocker, the most frequent cause of discontinuation (approximately 3 %) from treatment with Dorzolamide containing eye drops was drug-related ocular adverse effects, primarily conjunctivitis and lid reactions.



The following adverse reactions have been reported either during clinical trials or during post-marketing experience:



Very common (



Common (



Uncommon (



Rare (



Very rare (< 1/10.000)



Not known (cannot be estimated from the available data)



Nervous system and psychiatric disorders



Common: headache



Rare: dizziness, paraesthesia



Eye disorders



Very Common: burning and stinging



Common: superficial punctate keratitis, tearing, conjunctivitis, eyelid inflammation, eye itching, eyelid irritation, blurred vision



Uncommon: iridocyclitis



Rare: irritation including redness, pain, eyelid crusting, transient myopia (which resolved upon discontinuation of therapy), corneal oedema, ocular hypotony, choroidal detachment following filtration surgery



Respiratory, thoracic, and mediastinal disorders



Rare: epistaxis



Gastrointestinal disorders



Common: nausea, bitter taste



Rare: throat irritation, dry mouth



Skin and subcutaneous tissue disorders



Rare: contact dermatitis, urticaria, pruritus, rash



Renal disorders



Rare: urolithiasis



General disorders and administration site conditions



Common: asthenia/fatigue



Rare: hypersensitivity: signs and symptoms of local reactions (palpebral reactions) and systemic allergic reactions including angioedema, shortness of breath, rarely bronchospasm



Laboratory findings



Dorzolamide was not associated with clinically meaningful electrolyte disturbances.



Paediatric patients: see 5.1



4.9 Overdose



Only limited information is available with regard to human overdosage by accidental or deliberate ingestion of dorzolamide hydrochloride. The following have been reported with oral ingestion: somnolence; topical application: nausea, dizziness, headache, fatigue, abnormal dreams, and dysphagia.



Treatment should be symptomatic and supportive. Electrolyte imbalance, development of an acidotic state, and possible central nervous system effects may occur. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: antiglaucoma preparations and miotics, carbonic anhydrase inhibitor



ATC code: S01E C03



Mechanism of action



Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CAII) found primarily in red blood cells (RBCs) but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion. The result is a reduction in intra-ocular pressure (IOP).



Dorzolamide contains dorzolamide hydrochloride, a potent inhibitor of human carbonic anhydrase II. Following topical ocular administration, dorzolamide reduces elevated intra-ocular pressure, whether or not associated with glaucoma. Elevated intra-ocular pressure is a major risk factor in the pathogenesis of optic nerve damage and visual-field loss. Dorzolamide does not cause pupillary constriction and reduces intra-ocular pressure without side effects such as night blindness, accommodative spasm. Dorzolamide has minimal or no effect on pulse rate or blood pressure.



Topically applied beta-adrenergic blocking agents also reduce IOP by decreasing aqueous humor secretion but by a different mechanism of action. Studies have shown that when dorzolamide is added to a topical beta-blocker, additional reduction in IOP is observed; this finding is consistent with the reported additive effects of beta-blockers and oral carbonic anhydrase inhibitors.



Pharmacodynamic effects



Clinical effects



Adult Patients:



In patients with glaucoma or ocular hypertension, the efficacy of dorzolamide given t.i.d. as monotherapy (baseline IOP



Paediatric Patients:



A three month, double-masked, active-treatment controlled, multicentre study was undertaken in 184 (122 for dorzolamide) paediatric patients from one week of age to < 6 years of age with glaucoma or elevated intraocular pressure (baseline IOP> 22 mmHg) to assess the safety of 'Dorzolamide' when administered topically t.i.d. (three times a day). Approximately half the patients in both treatment groups were diagnosed with congenital glaucoma; other common aetiologies were Sturge Weber syndrome, iridocorneal mesenchymal dysgenesis, aphakic patients. The distribution by age and treatments in the monotherapy phase was as follows:












 


Dorzolamide 2%




Timolol




Age cohort < 2 years




n=56



Age range: 1 to 23 months




Timolol GS* 0.25% n=27



Age range: 0.25 to 22 months




Age cohort




n=66



Age range: 2 to 6 years




Timolol 0.5% n=35



Age range: 2 to 6 years



* gel-forming solution



Across both age cohorts approximately 70 patients received treatment for at least 61 days and approximately 50 patients received 81-100 days of treatment.



If IOP was inadequately controlled on dorzolamide or timolol gel-forming solution monotherapy, a change was made to open-label therapy according to the following: 30 patients < 2 years were switched to concomitant therapy with timolol gel-forming solution 0.25% daily and dorzolamide 2% t.i.d.; 30 patients > 2 years were switched to 2% dorzolamide/0.5% timolol fixed combination b.i.d.



Overall, this study did not reveal additional safety concerns in paediatric patients.



In a clinical trial, approximately 20% of patients while on dorzolamide monotherapy were observed to experience drug related adverse affects, the majority of which were local, non-serious ocular effects such as ocular burning and stinging, injection and eye pain. A small percentage < 4% were observed to have corneal oedema or haze. Local reactions appeared similar in frequency to comparator.



In post marketing data, metabolic acidosis in the very young particularly with renal immaturity/impairment has been reported.



Efficacy results in paediatric patients suggest that the mean IOP decrease observed in the dorzolamide group was comparable to the mean IOP decrease observed in the timolol group even if a slight numeric disadvantage was observed for timolol.



Longer-term efficacy studies (> 12 weeks) are not available.



5.2 Pharmacokinetic Properties



Unlike oral carbonic anhydrase inhibitors, topical administration of dorzolamide hydrochloride allows for the drug to exert its effects directly in the eye at substantially lower doses and therefore with less systemic exposure. In clinical trials, this resulted in a reduction in IOP without the acid-base disturbances or alterations in electrolytes characteristic of oral carbonic anhydrase inhibitors.



When topically applied, dorzolamide reaches the systemic circulation. To assess the potential for systemic carbonic anhydrase inhibition following topical administration, drug and metabolite concentrations in RBCs and plasma and carbonic anhydrase inhibition in RBCs were measured. Dorzolamide accumulates in RBCs during chronic dosing as a result of selective binding to CAII while extremely low concentrations of free drug in plasma are maintained. The parent drug forms a single N-desethyl metabolite that inhibits CAII less potently than the parent drug but also inhibits a less active isoenzyme (CAI). The metabolite also accumulates in RBCs where it binds primarily to CAI. Dorzolamide binds moderately to plasma proteins (approximately 33%). Dorzolamide is primarily excreted unchanged in the urine; the metabolite is also excreted in urine. After dosing ends, dorzolamide washes out of RBCs non linearly, resulting in a rapid decline of drug concentration initially, followed by a slower elimination phase with a half-life of about four months.



When dorzolamide was given orally to simulate the maximum systemic exposure after long-term topical ocular administration, steady state was reached within 13 weeks. At steady state, there was virtually no free drug or metabolite in plasma; CA inhibition in RBCs was less than that anticipated to be necessary for a pharmacological effect on renal function or respiration. Similar pharmacokinetic results were observed after chronic, topical administration of dorzolamide.



However, some elderly patients with renal impairment (estimated CrCl 30-60 ml/min) had higher metabolite concentrations in RBCs, but no meaningful differences in carbonic anhydrase inhibition, and no clinically significant systemic side effects were directly attributable to this finding.



5.3 Preclinical Safety Data



Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential.



In clinical studies, patients did not develop signs of metabolic acidosis or serum electrolyte changes that are indicative of systemic CA inhibition. Therefore, it is not expected that the effects noted in animal studies would be observed in patients receiving therapeutic doses of dorzolamide.



In rabbits, malformations of the vertebral bodies were observed at maternotoxic doses associated with metabolic acidosis.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Hydroxyethylcellulose



Mannitol



Sodium citrate



Sodium hydroxide/hydrochloric acid (for pH adjustment)



Benzalkonium chloride



Water for injections



6.2 Incompatibilities



Not applicable.



6.3 Shelf Life



2 years



After first opening: 4 weeks



From a microbiological point of view, once opened, the product may be stored for a maximum of 28 days. Other in-use storage times are the responsibility of the user.



6.4 Special Precautions For Storage



Keep the bottle in the outer carton, in order to protect from light.



6.5 Nature And Contents Of Container



Pack sizes



1 x 5 ml, 3 x 5 ml and 6 x 5 ml eye drops



LDPE bottle with LDPE dropper and HDPE cap.



Not all pack sizes may be marketed.



6.6 Special Precautions For Disposal And Other Handling



No special requirements.



See section 4.2 for patient instructions.



7. Marketing Authorisation Holder



Sandoz Ltd



Frimley Business Park,



Frimley,



Camberley,



Surrey,



GU16 7SR.



United Kingdom



8. Marketing Authorisation Number(S)



PL 04416/0757



9. Date Of First Authorisation/Renewal Of The Authorisation



18/04/2008



10. Date Of Revision Of The Text



11/2010




Doxorubicin 2 mg / ml Concentrate for Solution for Infusion





1. Name Of The Medicinal Product



Doxorubicin 2 mg/ml Concentrate for Solution for Infusion


2. Qualitative And Quantitative Composition



1 ml contains 2 mg Doxorubicin hydrochloride



Each 5 ml vial contains 10 mg of Doxorubicin hydrochloride.



Each 25 ml vial contains 50 mg of Doxorubicin hydrochloride.



Each 100 ml vial contains 200 mg of Doxorubicin hydrochloride.



Excipient: Contains sodium 3.5 mg/ml (0.15 mmol)



For full list of excipients, see section 6.1.



3. Pharmaceutical Form



Concentrate for solution for infusion



The product is a clear, red solution, with a pH in the range of 2.5-3.5 and osmolality between 270 mOsm/kg to 320 mOsm/kg.



4. Clinical Particulars



4.1 Therapeutic Indications



Doxorubicin is indicated in the following neoplastic conditions,



Examples include:



- Small-cell lung cancer (SCLC)



- Breast cancer



- Advanced ovarian carcinoma



- Intravesically for bladder cancer



- Neoadjuvant and adjuvant therapy of osteosarcoma



- Advanced soft-tissue sarcoma in adults



- Ewing's sarcoma



- Hodgkin's disease



- Non-Hodgkin's lymphoma



- Acute lymphatic leukaemia



- Acute myeloblastic leukaemia



- Advanced multiple myeloma



- Advanced or recurrent endometrial carcinoma



- Wilms' tumour



- Advanced papillary/follicular thyroid cancer



- Anaplastic thyroid cancer



- Advanced neuroblastoma



Doxorubicin is frequently used in combination chemotherapy regimens with other cytotoxic drugs.



4.2 Posology And Method Of Administration



Doxorubicin Injection should be administered only under the supervision of a qualified physician with extensive experience in cytotoxic treatment. Also, patients must be carefully and frequently monitored during the treatment (see section 4.4)



Due to the risk of often lethal cardiomyopathy, the risks and benefits of the individual patient should be weighted before each application.



Doxorubicin is administered intravenously and intravesically and must not be administered orally, subcutaneously, intramuscularly or intrathecally. Doxorubicin can be administered intravenously as bolus within minutes, as short infusion for up to an hour or as continuous infusion for up to 96 hours.



The solution is given via the tubing of a freely running intravenous infusion of sodium chloride 9 mg/ml (0.9%) solution for injection or dextrose 50 mg/ml (5%) solution for injection within 2 to 15 minutes. This technique minimises the risk of thrombophlebitis or perivenous extravasation, which can lead to severe local cellulites, vesication and tissue necrosis. A direct intravenous injection is not recommended due to the risk of extravasation, which may occur even in the presence of adequate blood return upon needle aspiration.



Intravenous administration use:



The dosage of doxorubicin depends on dosage regimen, general status and previous treatment of the patient. Dose schedule of doxorubicin hydrochloride administration could vary according to indication (solid tumors or acute leukemia) and according to its use in the specific treatment regimen (as single agent or in combination with other cytotoxic agents or as a part of multidisciplinary procedures that include combination of chemotherapy, surgical procedure and radiotherapy and hormonal treatment).



Monotherapy



Dosage is usually calculated on the basis of body surface area (mg/m2). On this basis, a dose of 60 - 75 mg/m2 body surface area is recommended every three weeks when doxorubicin is used as a single agent.



Combination regimen



When doxorubicin hydrochloride is administered in combination with other antitumour agents with overlapping toxicity, such as high-dose i.v. cyclophosphamide or related anthracycline compounds such as daunorubicin, idarubicin and/or epirubicin, the dosage of doxorubicin should be reduced to 30-60 mg/m2 every 3 – 4 weeks.



In patients, who cannot receive the full dose (eg. in case of immunosuppression, old age), an alternative dosage is 15-20 mg/m² body surface per week.



Intravesical administration:



Doxorubicin may be used by intravesical instillation for the treatment of superficial bladder carcinoma or in prophylaxis of tumor recurrence after transurethral resection (T.U.R) in patients with high risk of recurrence. The recommended doxorubicin hydrochloride dose for local intravesical treatment of superficial bladder tumors is instillation of 30-50 mg in 25-50 ml of sodium chloride 9 mg/ml (0.9%) solution for injection. The optimal concentration is about 1 mg/ml. Generally the solution should be retained intravesically for 1 to 2 hours. During this period the patient should be turned 90° every 15 minutes. The patient should not drink fluids for 12 hours prior to the treatment to avoid undesired dilution with urine (this should reduce the production of urine to about 50 ml/h). The instillation may be repeated with an interval of 1 week to 1 month, dependent on whether the treatment is therapeutic or prophylactic.



Patients with impaired hepatic function



Since doxorubicin hydrochloride is mainly excreted via liver and bile, the elimination of the medicinal product may be decreased in patients with hepatic function impairment or bile flow obstruction and this could result in severe secondary effects.



General dose adjustment recommendations in patients with hepatic function impairment are based on serum bilirubin concentration:










Serum Bilirubin




Recommended Dose




20-50 micro mole/L




½ normal dose




> 50 micro mol/L




¼ normal dose



Doxorubicin is contraindicated in patients with severe liver function disorder (see section 4.3).



Patients with impaired renal function



In patients with renal insufficiency (GFR < 10 ml/min), only 75% of the planned dose should be given.



In order to avoid cardiomyopathy, it is recommended that the cumulative total lifetime dose of Doxorubicin (including related drugs such as daunorubicin) should not exceed 450-550mg/m2 body surface area. If a patient with concomitant heart disease receives mediastinal and/or heart irradiation, prior treatment with alkylating agents, and high-risk patients (with arterial hypertension since > 5 years, with prior coronary, valvular or myocardial heart damage, age over 70 years) with a maximum total dose of 400 mg/m2 body surface area should not be exceeded and the cardiac function of these patients should be monitored (see section 4.4).



Dose in children



Dosage in children may need to be reduced, please refer to treatment protocols and the specialist literature.



Obese patients



A reduced starting dose or prolonged dose interval might need to be considered in obese patients (see section 4.4).



4.3 Contraindications



Hypersensitivity to the active substance doxorubicin hydrochloride or to any of the excipients



Contraindications for intravenous administration:



• Hypersensitivity to anthracendiones or other anthracyclines



• Marked persisting myelosuppression and/or severe stomatitis induced by previous treatment with other cytotoxic agents and/or radiation



• Previous treatment with anthracyclines up to their maximum cumulative dose



• Generalized infection



• Severe impaired liver function



• Severe arrhythmias, heart failure, previous myocardial infarction, acute inflammatory heart disease



• Increased haemorrhagic tendency



• Breast-feeding (see section 4.6)



Contraindications for intravesical administration:



• Invasive tumors that have penetrated the bladder (beyond T1)



• Bladder inflammation



• Haematuria



• Difficult urinary catheter introduction (e.g. in large intravesical tumors)



• Breast-feeding (see section 4.6)



• Urinary tract infections



Doxorubicin may not be given during pregnancy and lactation (see section 4.6).



4.4 Special Warnings And Precautions For Use



Doxorubicin Injection should be administered only under the supervision of a qualified physician experienced in cytotoxic therapy for i.v. or intravesical use. Doxorubicin hydrochloride may potentiate the toxicity of other anticancer therapies. A careful control of possible clinical complications should be performed, particularly in elderly patients, in patients with a history of heart disease, or with bone-marrow suppression, or patients who previously have been treated with anthracyclines, or treated with radiation in the mediastinum.



Initial treatment with doxorubicin requires close observation of the patient and extensive laboratory monitoring. It could be recommended therefore, that patients be hospitalised at least during the first phase of treatment. Doxorubicin may cause infertility during the time of drug administration.



Patients should recover from the acute toxicities of prior cytotoxic treatment (such as stomatitis, neutropenia. thrombocytopenia. and generalized infections) before beginning treatment with doxorubicin.



Before or during treatment with doxorubicin the following monitoring examinations are recommended (how often these examinations are done will depend on the general condition, the dose and the concomitant medication):



• radiographs of the lungs and chest and ECG



• regular monitoring of heart function (LVEF by e.g. ECG, UCG and MUGA scan)



• daily inspection of the oral cavity and pharynx for mucosal changes



• blood tests: haematocrit, platelets, differential white cell count, SGPT, SGOT, LDH, bilirubin, uric acid.



Treatment control



Prior to start of the treatment it is recommended to measure the liver function by using conventional tests such as AST, ALT, ALP and bilirubin as well as the renal function, (see section 4.4).



Control of the left ventricular function



Analysis of LVEF using ultrasound or heart scintigraphy should be performed in order to optimise the heart condition of the patient. This control should be made prior to the start of the treatment and after each accumulated dose of approximately 100 mg/m2 (see section 4.4).



Cardiac Function



Cardiotoxicity is a risk of anthracycline treatment that may be manifested by early (i.e. acute) or late (i.e. delayed) events.



Early (i.e. Acute) Events: Early cardiotoxicity of doxorubicin consists mainly of sinus tachycardia and/or ECG abnormalities such as non-specific ST-T wave changes. Tachyarrhythmias, including premature ventricular contractions and ventricular tachycardia, bradycardia, as well as atrioventricular and bundle-branch block have also been reported. These symptoms generally indicate acute transient toxicity. Flattening and widening of the QRS-complex beyond normal limits may indicate doxorubicin hydrochloride-induced cardiomyopathy. As a rule, in patients with a normal LVEF baseline value (=50%), a 10% decrease of absolute value or dropping below the 50% threshold indicates cardiac dysfunction and in such situation treatment with doxorubicin hydrochloride should be carefully considered.



Late (i.e. Delayed) Events: Delayed cardiotoxicity usually develops late in the course of therapy with doxorubicin or within 2 to 3 months after treatment termination, but later events, several months to years after completion of treatment, have also been reported. Delayed cardiomyopathy is manifested by reduced left ventricular ejection fraction (LVEF) and/or signs and symptoms of congestive heart failure (CHF) such as dyspnoea, pulmonary oedema, dependent oedema, cardiomegaly and hepatomegaly, oliguria, ascites, pleural effusion and gallop rhythm. Subacute effects such as pericarditis/myocarditis have also been reported. Life-threatening CHF is the most severe form of anthracycline-induced cardiomyopathy and represents the cumulative dose-limiting toxicity of the drug.



Cardiac function should be assessed before patients undergo treatment with doxorubicin and must be monitored throughout therapy to minimize the risk of incurring severe cardiac impairment. The risk may be decreased through regular monitoring of LVEF during the course of treatment with prompt discontinuation of doxorubicin at the first sign of impaired function. The appropriate quantitative method for repeated assessment of cardiac function (evaluation of LVEF) includes multi-gated radionuclide angiography (MUGA) or echocardiography (ECHO). A baseline cardiac evaluation with an ECG and either a MUGA scan or an ECHO is recommended, especially in patients with risk factors for increased cardiotoxicity. Repeated MUGA or ECHO determinations of LVEF should be performed, particularly with higher, cumulative anthracycline doses. The technique used for assessment should be consistent throughout follow-up.



The probability of developing CHF, estimated around 1% to 2% at a cumulative dose of 300 mg/m2 slowly increases up to the total cumulative dose of 450-550 mg/m2. Thereafter, the risk of developing CHF increases steeply and it is recommended not to exceed a maximum cumulative dose of 550 mg/m2. If the patient has other potential risk factors of cardiotoxicity (history of cardiovascular disease, previous therapy with other anthracyclines or anthracenediones, prior or concomitant radiotherapy to the mediastinal/pericardial area, and concomitant use of medicinal products with the ability to suppress cardiac contractility, including cyclophosphamide and 5-fluoruracil), cardiotoxiciry with doxorubicin may occur at lower cumulative doses and cardiac function should be carefully monitored.



It is probable that the toxicity of doxorubicin and other anthracyclines or anthracenediones is additive.



Liver function



The major route of elimination of doxorubicin is the hepatobiliary system. Serum total bilirubin should be evaluated before and during treatment with doxorubicin. Patients with elevated bilirubin may experience slower clearance of the drug with an increase in overall toxicity. Lower doses are recommended in these patients (see section 4.2). Patients with severe hepatic impairment should not receive doxorubicin (see section 4.3).



Haematologic Toxicity



Doxorubicin may produce myelosuppression (See Section 4.8) Haetnatologic profiles should be assessed before and during each cycle of therapy with doxorubicin, including differential white blood cell (WBC) counts. A dose-dependent, reversible leucopenia and/or granulocytopenia (neutropenia) is the predominant manifestation of doxorubicin haematologic toxicity and is the most common acute dose-limiting toxicity of this drug. Leucopenia and neutropenia generally reach the nadir between days 10 and 14 after drug administration; the WBC/neutrophil counts return to normal values in most cases by day 21. Dose reduction or increase of the dose interval should be considered if the blood values are not normalised. Thrombocytopenia and anaemia may also occur. Clinical consequences of severe myelosuppression include fever, infections, sepsis/septicaemia, septic shock, haemorrhage, tissue hypoxia or death.



Secondary leukaemia



Secondary leukaemia with or without a preleukaemic phase, has been reported in patients treated with anthracyclines (including doxorubicin). Secondary leukaemia is more common when such medicinal products are given in combination with other DNA-damaging antineoplastic agents, when patients have been heavily pretreated with cytotoxic medicinal products or when doses of the anthracyclines have been escalated. These leukaemias can have a 1 to 3 year latency period.



Intravesical administration



Intravesical administration of doxorubicin may cause symptoms of chemical cystitis (i.e. dysuria, urinary frequency, nocturia, stranguria, haematuria, necrosis of the bladder wall). Special attention is needed in case of catheter problems (i.e. urethral obstruction caused by invasion of intravesical tumour). Intravesical administration is contraindicated for tumours that have penetrated the bladder (beyond T1).



Tile intravesical route of administration should not be attempted in patients with, invasive tumours that have penetrated the bladder wall, urinary tract infections, and inflammatory conditions of the bladder.



Control of serum uric acid:



During therapy serum uric acid may increase. In case of hyperuricemia antihyperuricemic therapy should be initiated.



In patients with severely impaired renal function dose reductions may be necessary (see section 4.2).



Gastrointestinal effects



An antiemetic prophylaxis is recommended.



Note: Doxorubicin should not be used in the presence in inflammations, ulcerations or diarrhoea.



Extravasation



Perivenous misinjection results in local necrosis and thrombophlebitis. A burning sensation in the region of the infusion needle is indicative of perivenous administration. If extravasation occurs, the infusion or injection has to be stopped at once; the needle should be left in place for a short time and then be removed after short aspiration. In case of extravasation start intravenous infusion of dexrazoxane, no later than 6 hours after extravasation (see the SmPC of dexrazoxane for dosing and further information). In case dexrazoxane is contraindicated, it is recommended to apply 99% dimethylsulfoxide (DMSO) locally to an area twice the size of the area concerned (4 drops to 10 cm² of skin surface area) and to repeat this three times a day for a period of no less than 14 days. If necessary, debridement should be considered. Because of the antagonistic mechanism, the area should be cooled after the application of DMSO (vasoconstriction vs. vasodilatation), e.g., to reduce pain. Do not use DMSO in patients who are receiving dexrazoxane to treat anthracycline-induced extravasation. Other measures have been treated controversially in the literature and have no definite value.



Radiotherapy



Radiation-induced toxicities (myocardium, mucosa, skin and liver) have also been reported. Special caution is mandatory for patients who have had radiotherapy previously, are having radiotherapy concurrently or are planning to have radiotherapy. These patients are at special risk of local reactions in the radiation field (recall phenomenon) if doxorubicin hydrochloride is used. Severe, sometimes fatal, hepatotoxicity (liver damage) has been reported in this connection. Prior radiation to the mediastinum increases the cardiotoxicity of doxorubicin. The cumulative dose of 400 mg/m² must not be exceeded especially in this case.



Infertility



Doxorubicin can have genotoxic effects. Doxorubicin may cause infertility during the time of drug administration. In women, doxorubicin may cause amenorrhea. Although ovulation and menstruation appear to return after termination of therapy, premature menopause can occur. Women should not become pregnant during and up to 6 months after treatment.



Doxorubicin is mutagenic and can induce chromosomal damage in human spermatozoa. Oligospermia or azoospermia may be permanent; however, sperm counts have been reported to return to normospermic levels in some instances. This may occur several years after the end of therapy. Men undergoing doxorubicin treatment should use effective contraceptive measures. Also are advised not to father a child during and up to 6 months after treatment and to seek advice on cryo-conservation (or cryo-preservation) of sperm prior to treatment because of the possibility of irreversible infertility due to therapy with doxorubicin.



Anticancer therapies:



Doxorubicin may potentiate the toxicity of other anticancer therapies. Exacerbation of cyclophosphamide-induced haemorrhagic cystitis and enhanced hepatotoxicity of 6-mercaptopurine have been reported, as with other cytotoxic agents, thrombophlebitis and thromboembolic phenomena including pulmonary embolism (in some cases fatal) have been coincidentally reported with the use of doxorubicin (see section 4.8).



Vaccines:



This medicinal product is generally not recommended in combination with live, attenuated vaccines.



Contact to persons recently vaccinated against polio should be avoided.



Other:



The systemic clearance of doxorubicin is reduced in obese patients (i.e. >130% ideal body weight) (see section 4.2).



Doxorubicin may induce hyperuricaemia as a consequence of the extensive purine catabolism that accompanies drug-induced rapid lysis of neoplastic cells (tumour-lysis syndrome) (see section 4.8). Blood uric acid levels, potassium, calcium phosphate and creatinine should be evaluated after initial treatment. Hydration, urine alkalinization, and prophylaxis with allopurinol to prevent hyperuricaemia may minimize potential complications of tumour lysis syndrome.



A stinging or burning sensation at the site of administration may signify a small degree of extravasation. If extravasation is suspected or occurs, the injection should be discontinued and restarted in a different blood vessel. Cooling the area for 24 hours can reduce the discomfort. The patient should be carefully monitored for several weeks. Surgical measures might be necessary.



Doxorubicin hydrochloride may impart a red colour to the urine. Patients should be cautioned that this does not pose any health hazards.



Dosage should not be repeated in the presence or development of bone marrow depression or buccal ulceration. The latter may be preceded by premonitory buccal burning sensations and repetition in the presence of this symptom is not advised.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Doxorubicin cardiotoxicity is enhanced by previous or concurrent use of other anthracyclines, or other potentially cardiotoxic drugs (e.g. 5-fluorouracile, cyclophosphamide or paclitaxel) or with products affecting cardiac function (like calcium antagonists), When doxorubicin is used together with the above mentioned agents, cardiac function must be followed carefully.



The use of trastuzumab in combination with anthracyclines (such as doxorubicin) is associated with a high cardiotoxic risk. Trastuzumab and anthracyclines should not be used in combination for the time being, except in well controlled clinical studies where the cardiac function is monitored. When anthracyclines are used after the end of a therapy with trastuzumab, an elevated risk of cardiotoxicity may result. If possible, there should be a sufficiently long interval (up to 22 weeks) between the end of a therapy with trastuzumab and the beginning of the anthracycline therapy. Careful monitoring of the cardiac function is imperative.



Doxorubicin hepatotoxicity may be enhanced by other hepatotoxic treatment modalities (e.g. 6-mercaptopurine).



Doxorubicin undergoes metabolism via Cytochrome P450 (CYP450) and is a substrate for the Pgp transporter, Concomitant administration of inhibitors of CYP450 and/or Pgp might lead to increased plasma concentrations of doxorubicin and thereby increased toxicity. Conversely, concomitant administration of inducers of CYP450, such as rifampicin and barbiturates, might decrease plasma concentrations of doxorubicin and reduce efficacy.



Ciclosporin, an inhibitor of CYP3A4 and Pgp, increased the AUC of doxorubicin and doxorubicinol by 55% and 350%, respectively. The combination might require dose adjustment. Cimetidine has also been shown to reduce the plasma clearance and increase the AUC of doxorubicin.



Paclitaxel administered shortly before doxorubicin may decrease clearance and increase plasma concentrations of doxorubicin. Some data indicate that this interaction is less pronounced when doxorubicin is administered before paclitaxel.



Barbiturates may lead to an accelerated plasma clearance of doxorubicin, while the concomitant administration of phenytoin may result in lower plasma phenytoin levels.



Elevated serum doxorubicin concentrations were reported after the concomitant administration of doxorubicin and ritonavir.



The toxic effects of a doxorubicin therapy may be increased in a combination with other cytostatics (e.g. cytarabine, cisplatin, and cyclophosphamide). Necroses of the large intestine with massive haemorrhage and severe infections may occur in connection with combination therapies with cytarabine.



Clozapine may increase the risk and severity of the hematologic toxicity of Doxorubicin.



Marked nephrotoxicity of Amphotericin B can occur during doxorubicin therapy.



As doxorubicin is rapidly metabolised and predominantly eliminated by the biliary system, the concomitant administration of known hepatotoxic chemotherapeutic agents (e.g. mercaptopurine, methotrexate, streptozocin) could potentially increase the toxicity of doxorubicin as a result of reduced hepatic clearance of the drug. Dosing of doxorubicin must be modified if concomitant therapy with hepatotoxic drugs is mandatory.



Doxorubicin is a potent, radio sensitizing agent (“radio sensitizer”), and recall phenomena induced by it may be life-threatening. Any preceding, concomitant or subsequent radiation therapy may increase the cardiotoxicity or hepatotoxicity of doxorubicin. This applies also to concomitant therapies with cardiotoxic or hepatotoxic drugs.



Doxorubicin may cause exacerbations of hemorrhagic cystitis caused by previous cyclophosphamide therapy.



Doxorubicin therapy may lead to increased serum uric acid, therefore dose adjustment of uric acid lowering agents may be necessary.



Doxorubicin may reduce oral bioavailability of digoxin.



During treatment with Doxorubicin patients should not be actively vaccinated and also avoid contact with recently polio vaccinated persons.



4.6 Pregnancy And Lactation



Pregnancy



Doxorubicin has been found in foetal tissue (liver, kidney, lungs) at concentrations several times those in maternal plasma indicating that it does pass the placenta. In animals studies, doxorubicin has shown embryo-, foeto- and teratogenic effects (see section 5.3) and also proved to be highly mutagenic in the Ames test. Doxorubicin hydrochloride is contraindicated in pregnancy. In general, cytostatics should only be administered during pregnancy on strict indication, and the benefit to the mother weighed against possible hazards to the foetus.



For safety reasons, men wanting a baby should preserve unexposed sperm prior to treatment with doxorubicin and abstain from engendering a child during and 6 months after therapy. Women with childbearing potential have to use effective contraception during doxorubicin therapy and 6 months after treatment.



Lactation



Doxorubicin has been reported to be excreted in human breast milk. A risk to the suckling child cannot be excluded. Since the use of doxorubicin hydrochloride during breast-feeding is contraindicated, breast-feeding should be discontinued during treatment with doxorubicin (see section 4.3).



4.7 Effects On Ability To Drive And Use Machines



Due to the frequent occurrence of nausea and vomiting, driving cars and operation of machinery should be discouraged.



4.8 Undesirable Effects



Treatment with doxorubicin often causes undesirable effects, and some of these effects are serious enough to entail careful monitoring of the patient. The frequency and kind of undesirable effects are influenced by the speed of administration and the dosage. Bone-marrow suppression is an acute dose limiting adverse effect, but is mostly transient. Clinical consequences of doxorubicin bone marrow/haematological toxicity may be fever, infections, sepsis/septicaemia, septic shock, haemorrhages, tissue hypoxia or death. Nausea and vomiting as well as alopecia are seen in almost all patients.



The following adverse events have been reported in association with doxorubicin therapy:



Frequencies are defined using the following convention:



Very common (



Common (



Uncommon (



Rare (



Very rare (<1/10,000), not known (cannot be estimated from the available data)

























































































 




Common




Uncommon




Rare




Not known




Infections and infestations




Sepsis, septiciaemia



 

 

 


Neoplasms benign and malignant



 

 


Secondary leukaemia when in combination with anti-neoplastic drugs which damage the DNA. (see section 4.4), tumour lysis syndrome



 


Blood and lymphatic system disorders:




bone-marrow suppression, leucopenia and neutropenia



 

 


Thrombocytopenia, anaemia




Immune System disorders



 

 


Anaphylactic reactions



 


Endocrine disorders



 

 

 


Hot flushes




Eye disorders



 

 


Conjunctivitis



 


Cardiac disorders




cardiomyopathy, (2%: e.g. decrease of LVEF. dyspnoea);



ECG changes (e.g. sinus tachycardia, tachyarrhythmia, ventricular tachycardia, bradycardia, bundle branch block)



 

 


arrhythmia, heart failure




Vascular disorder's



 


phlebitis



 


Thrombophlebitis; thromboembolism




Gastrointestinal disorders




nausea: vomiting; mucositis; anorexia: diarrhoea




Gastrointestinal haemorrhage, abdominal pain: ulceration of the mucous membranes in the mouth, pharynx , oesophagus and gastrointestinal tract may appear in combination with cytarabine, ulceration and necrosis of the colon, in particular the caecum, have been reported (see section 4.5)



 

 


Respiratory, thoracic and mediastinal disorders



 

 

 


Bronchospasm, radiation pneumonitis




Skin and subcutaneous tissue disorder's:




alopecia




Itching, local hypersensitivity reaction of the field of radiation (recall phenomenon)




urticaria, exanthema, local erythematous reactions along the vein which was used for the injection, hyperpigmentation of skin and nails, onycholysis




tissue hypoxia




Renal and urinary disorders:




local reactions (chemical cystitis) might occur at intravesical treatment (i.e. dysuria, urinary frequency, nocturia, stranguria, haematuria, necrosis of the bladder wall)



 

 


acute renal failure, hyperuricaemia (see section 4.4)




Reproductive system and breast disorders



 

 

 


Amenorrhoea, oligospermia, azoospermia (see section 4.4)




General disorders and administration site conditions:



 


dehydratation




anaphylactic reactions, shivering, fever, dizziness




A stinging or burning sensation at the administration site (see section 4.4)



Malaise/weakness




Hepatobiliar disorders



 

 

 


Hepatotoxicity, transient increase of liver enzymes




Surgical and medical procedure



 

 

 


Extravasation can lead to severe cellulitis, vesication and local tissue necrosis which may require surgical measures (including skin grafts) (see section 4.4)



4.9 Overdose



Acute overdosage of doxorubicin may lead to myelosuppression (particularly leucopenia and thrombocytopenia), generally 10 - 14 days following overdose, gastrointestinal toxic effects (particularly mucositis) and acute cardiac alterations, which may occur within 24 hours. Treatment includes intravenous antibiotics, transfusion of granulocytes and thrombocytes and treatment of the gastrointestinal symptoms and heart effects. Moving the patient to a sterile room and the use of a haemopoietic growth factor should be considered.



Single doses of 250 mg and 500 mg of doxorubicin have proved fatal.



Chronic overdosage, with a cumulative dose exceeding 550 mg/m2 increases the risk for cardiomyopathy and may lead to heart failure, which should be treated along conventional lines.



Delayed cardiac failure may occur up to six months after the overdosage.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: Anthracyclines and related substances



ATC code: L01DB01



Doxorubicin is an anthracycline antibiotic. The mechanism of action is not completely elucidated. It is postulated that doxorubicin hydrochloride exerts its antineoplastic effect via cytotoxic mechanisms of action especially intercalation into DNA, inhibition of the enzyme topoisomerase II, and formation of reactive oxygen species (ROS). All of these have a deleterious effect on DNA synthesis: Intercalation of the doxorubicin molecule leads to all inhibition of RNA and DNA polymerases by way of disturbances in base recognition and sequence specificity. The inhibition of topoisomerase II produces single and double strand breaks of the DNA helix. Scission of DNA also originates from the chemical reaction with highly reactive oxygen species like the hydroxyl radical OH•. Mutagenesis and chromosomal aberrations are the consequences.



The specificity of doxorubicin toxicity appears to be related primarily to proliferative activity of normal tissue. Thus, bone marrow, gastro-intestinal tract and gonads are the main normal tissues damaged.



An important cause of treatment failure with doxorubicin and other anthracyclines is the development of resistance. In an attempt to overcome cellular resistance to doxorubicin, the use of calcium antagonists such as verapamil has been considered since the primary target is the cell membrane. Verapamil inhibits the slow channel of calcium transport and can enhance cellular uptake of doxorubicin. A combination of doxorubicin and verapamil is associated with severe cardiotoxic effects.



5.2 Pharmacokinetic Properties



Distribution



Following intravenous injection, doxorubicin is rapidly cleared from the blood and widely distributed into tissues including lungs, liver, heart, spleen, lymph nodes, bone marrow and kidneys. The volume of distribution is about 25 litres. The degree of protein binding is 60-70%.



Doxorubicin does not cross the blood-brain barrier, although higher levels in liquor may be reached in the presence of brain metastases or leukemic cerebral dissemination. Doxorubicin is rapidly distributed into the ascites, where it reaches higher concentrations than in plasma. Doxorubicin is secreted into breast milk.



Elimination



The elimination of doxorubicin from the blood is triphasic with mean half-lives of 12 minutes (distribution), 3.3 hours and about 30 hours. Doxorubicin undergoes rapid metabolism in the liver. The main metabolite is the pharmacologically active doxorubicinol. Other metabolites are deoxyrubicin aglycone, glucuronide and sulphate conjugate. About 40 to 50% of a dose is excreted in bile within 7 days, of which about half is excreted as unchanged drug and the rest as metabolites. Only 5-15% of the administered dose is eliminated in urine.



Special populations



As the elimination of doxorubicin is mainly hepatic, impairment of liver function results in slower excretion, and consequently, increased retention and accumulation in plasma and tissues. Dose reduction is generally advised.



Although renal excretion is a minor elimination pathway for doxorubicin, severe renal impairment might affect total elimination and require dose reduction.



In a study in obese patients (>130% of ideal bodyweight) the doxorubicin clearance was reduced and the half life increased compared with a normal-weight control group. Dose adjustments might be necessary in the obese.



5.3 Preclinical Safety Data



Animal studies from literature show that Doxorubicin affects the fertility, is embryo- and foetotoxic and teratogenic. Other data shows that Doxorubicin is mutagenic.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Sodium chloride



Hydrochloric acid (for pH adjustment)



Water for injections



6.2 Incompatibilities



Doxorubicin should not be mixed with heparin, as a precipitate may form and it should not be mixed with 5-fluorouracil as degradation may occur. Prolonged contact with any solution of an alkaline pH should be avoided, as it will result in hydrolysis of the drug.



Until detailed compatibility information about miscibility is available, Doxorubicin should not be mixed with other medicinal products than those mentioned under section 6.6.



6.3 Shelf Life



Unopened vials: 18 months



Opened vials: The product should be used immediately after opening the vial.



Prepared infusion solutions:



Chemical and physical in-use stability has been demonstrated in 0.9% sodium chloride injection and 5% dextrose injection for up to 28 days at 2 – 8°C and for up to 7 days at 25°C when prepared in glass containers protected from light.



From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless dilution has taken place in controlled and validated aseptic condition.



6.4 Special Precautions For Storage



Store in a refrigerator (2°C - 8°C).



Keep the vial in the outer carton in order to protect from light.



For storage conditions of the diluted medicinal product, see section 6.3.



6.5 Nature And Contents Of Container



For 5 ml,



Concentrate for solution for infusion is filled in 5 ml Type - I clear tubular glass vial closed with chlorobutyl rubber stopper with teflon coating and aluminium flip off pink seal.



For 25 ml,



Concentrate for solution for infusion is filled in 30 ml Type - I clear molded glass vial closed with chlorobutyl rubber stopper with teflon coating and aluminium flip off pink seal.



For 100 ml,



Concentrate for solution for infusion is filled in 100 ml Type - I clear molded glass vial closed with chlorobutyl rubber stopper with teflon coating and aluminium flip off pink seal.



Pack sizes:



1 × 5 ml vial



1 × 25 ml vial



1 × 100 ml vial



Not all pack sizes may be marketed.



6.6 Special Precautions For Disposal And Other Handling



Doxorubicin is a potent cytotoxic agent which should only be prescribed, prepared and administered by professionals who have been trained in the safe use of the preparation. The following guidelines should be followed when handling, preparing and disposing of doxorubicin.



Preparation



1. Personnel should be trained in good technique for handling.



2. Pregnant staff should be excluded from working with this drug.



3. Personnel handling doxorubicin should wear protective clothing: goggles, gowns, disposable gloves and masks.



4. All items used for administration or cleaning, including gloves, should be placed in high risk waste disposal bags for high temperature (700°C) incineration.



5. All cleaning materials should be disposed of as indicated previously.



6. Always wash han

Dulcoease 100 mg Capsules





1. Name Of The Medicinal Product



Dulcoease, 100 mg capsules


2. Qualitative And Quantitative Composition



Docusate sodium 100 mg.



For excipients, see Section 6.1.



3. Pharmaceutical Form



Capsules



A two colour (opaque white and opaque yellow) soft, oval, gelatin capsule with a clear, colourless liquid fill.



4. Clinical Particulars



4.1 Therapeutic Indications



a) To prevent and treat chronic constipation.










 




(i)




to soften hard, dry stools in order to ease defaecation and reduce straining at stool; and




 




(ii)




in the presence of haemorrhoids and anal fissure, to prevent hard, dry stools and reduce straining.



b) As an adjunct in abdominal radiological procedures.



4.2 Posology And Method Of Administration



Route of administration: Oral



Adults and elderly:



Up to 500 mg should be taken daily in divided doses. Treatment should be commenced with large doses, which should be decreased as the condition of the patient improves.



For use with barium meals:



400 mg to be taken with the meal.



Children under 12 years:



Not recommended.



4.3 Contraindications



These capsules should not be administered when abdominal pain, nausea, vomiting or intestinal obstruction is present.



This product should not be given to patients with a known hypersensitivity to DulcoEase capsules or any of the components.



Patients with rare hereditary problems of fructose intolerance should not take this medicine.



4.4 Special Warnings And Precautions For Use



Organic disorders should be excluded prior to the administration of any laxative.



The treatment of constipation with any medicinal product is only adjuvant to a healthy lifestyle and diet, for example:



• Increased intake of fluids and dietary fibre.



• Advice on appropriate physical activity



If laxatives are needed every day, or if there is persistent abdominal pain, consult your doctor.



Contains sorbitol: do not use this medicine if you are intolerant to small quantities of sugar (sorbitol, fructose).



Contains colouring E110 which may cause allergic reactions.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



These capsules should not be taken concurrently with mineral oil.



4.6 Pregnancy And Lactation



There are no adequate data from the use of the drug in pregnant women. Animal studies are insufficient with respect to effects on pregnancy and embryonic foetal development. The potential risk for humans is unknown. During wide use, no adverse consequences have been reported.



Use in pregnancy only if the benefits outweigh the risks.



Docusate sodium is excreted in breast milk and should therefore, be used with caution in lactating mothers.



4.7 Effects On Ability To Drive And Use Machines



None known.



4.8 Undesirable Effects



Rarely, these capsules can cause diarrhoea, nausea, abdominal cramps or skin rash.



4.9 Overdose



In rare cases of overdose, excessive loss of water and electrolytes should be treated by encouraging the patient to drink plenty of fluid.



Electrolyte loss should be replenished where appropriate.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



ATC code: A06A02 Laxatives, softeners, emollients



Docusate sodium is an anionic wetting agent, which acts as a faecal softener by lowering the surface tension and allowing penetration of accumulated hard dry faeces by water and salts.



Docusate Sodium also possesses stimulant activity.



5.2 Pharmacokinetic Properties



Docusate sodium exerts its clinical effect in the gastrointestinal tract. There is some evidence that docusate sodium is absorbed and is excreted in the bile. There is also evidence that docusate sodium is capable of enhancing absorption of certain compounds administered concomitantly



5.3 Preclinical Safety Data



None stated.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Macrogol 400



Propylene glycol



Gelatin 195 bloom



Purified water



Sorbitol special



Glycerol



Titanium dioxide E171



Quinoline yellow E104



Sunset yellow E110



6.2 Incompatibilities



None.



6.3 Shelf Life



PVC / PVDC blister packs with aluminium foil: 18 months.



Polyethylene / polypropylene containers: 36 months.



6.4 Special Precautions For Storage



Do not store above 25ÂșC. Store in the original package in order to protect from moisture.



6.5 Nature And Contents Of Container



PVC/PVDC blister packs with aluminium foil containing 10, 20, 30, 40 or 50 capsules.



Polyethylene / polypropylene containers, e.g.: securitainers / tampertainers containing 100 and 250 capsules.



Not all pack sizes may be marketed.



6.6 Special Precautions For Disposal And Other Handling



None



7. Marketing Authorisation Holder



UCB Pharma Limited



208 Bath Road,



Slough,



Berkshire,



SL1 3WE



United Kingdom



8. Marketing Authorisation Number(S)



PL 00039/0737



9. Date Of First Authorisation/Renewal Of The Authorisation



28 February 2008



10. Date Of Revision Of The Text



October 2009




DULCOLAX Suppositories, 10 mg





1. Name Of The Medicinal Product



DULCOLAX 10 mg Suppositories


2. Qualitative And Quantitative Composition



Smooth white torpedo shaped suppositories, each containing 10 mg of bisacodyl



3. Pharmaceutical Form



Suppositories for rectal administration.



4. Clinical Particulars



4.1 Therapeutic Indications



Constipation, either chronic or of recent onset, whenever a stimulant laxative is required.



Bowel clearance before surgery or radiological investigation. Replacement of the evacuant enema in all its indications.



4.2 Posology And Method Of Administration



Children aged 10 years or younger with chronic or persistent constipation should only be treated under the guidance of a physician. Bisacodyl should not be used in children aged 4 years or younger.



Short-term treatment for constipation:



Adults and children over 10 years: 1 to 2 coated tablets (5 - 10 mg) daily before bedtime, or 1 suppository (10 mg) for immediate effect.



Children 4 – 10 years: 1 coated tablet (5 mg) daily before bedtime, or 1 suppository (5 mg) for immediate effect.



For preparation of diagnostic procedures and preoperatively



Should only be used under medical supervision.



Adults and children over 10 years: 2 coated tablets (10 mg) in the morning and 2 coated tablets (10 mg) in the evening and 1 suppository (10 mg) on the following morning is recommended.



Children aged 4 -10 years of age: 1 coated tablet (5 mg) in the evening and 1 suppository (5 mg) on the following morning is recommended.



When using DULCOLAX to prepare the patient for radiographic examination of the abdomen or employing it preoperatively, tablets should be combined with suppositories in order to achieve complete evacuation of the intestine.



In the management of constipation, once regularity has been restarted dosage should be reduced and can usually be stopped.



It is recommended to take the coated tablets at night to have a bowel movement the following morning. They should be swallowed whole with an adequate amount of fluid.



The coated tablets should not be taken together with products which reduce the acidity of the upper gastrointestinal tract, such as milk, antacids or proton pump inhibitors, in order not to prematurely dissolve the enteric coating.



Suppositories are usually effective in about 20 minutes, but in some cases it may take up to 45 minutes. They should be unwrapped and inserted into the rectum pointed end first.



No specific information on the use of this product in the elderly is available. Clinical trials have included patients over 65 years and no adverse reactions specific to this age group have been reported.



4.3 Contraindications



DULCOLAX is contraindicated in patients with ileus, intestinal obstruction, acute abdominal conditions including appendicitis, acute inflammatory bowel diseases, and severe abdominal pain associated with nausea and vomiting which may be indicative of the aforementioned severe conditions.



DULCOLAX is also contraindicated in severe dehydration and in patients with known hypersensitivity to bisacodyl or any other component of the product.



DULCOLAX Suppositories should not be used when anal fissures or ulcerative proctitis with mucosal damage are present.



4.4 Special Warnings And Precautions For Use



As with all laxatives, DULCOLAX should not be used on a continuous daily basis for more than five days without investigating the cause of constipation.



Prolonged excessive use may lead to fluid and electrolyte imbalance and hypokalaemia.



Intestinal loss of fluids can promote dehydration. Symptoms may include thirst and oliguria. In patients suffering from fluid loss where dehydration may be harmful (e.g. renal insufficiency, elderly patients) DULCOLAX should be discontinued and only be restarted under medical supervision.



Patients may experience haematochezia (blood in stool) that is generally mild and self-limiting.



Dizziness and / or syncope have been reported in patients who have taken DULCOLAX. The details available for these cases suggest that the events would be consistent with defaecation syncope (or syncope attributable to straining at stool), or with a vasovagal response to abdominal pain related to the constipation, and not necessarily to the administration of bisacodyl itself.



There have been isolated reports of abdominal pain and bloody diarrhoea occurring after taking bisacodyl. Some cases have been shown to be associated with colonic mucosal ischaemia.



The use of suppositories may lead to painful sensations and local irritation, especially in anal fissures and ulcerative proctitis.



DULCOLAX should not be used by children under 10 years without medical advice.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



The concomitant use of antacids and milk products may reduce the resistance of the coating of the tablets and result in dyspepsia and gastric irritation.



The concomitant use of diuretics or adreno-corticosteroids may increase the risk of electrolyte imbalance if excessive doses of DULCOLAX are taken.



Electrolyte imbalance may lead to increased sensitivity to cardiac glycosides.



4.6 Pregnancy And Lactation



There are no adequate and well-controlled studies in pregnant women. Long experience has shown no evidence of undesirable or damaging effects during pregnancy.



Clinical data show that neither the active moiety of bisacodyl (BHPM or bis-(p-hydroxyphenyl)-pyridyl-2-methane) nor its glucuronides are excreted into the milk of healthy lactating females.



Nevertheless, as with all medicines, DULCOLAX should not be taken in pregnancy, especially the first trimester, and during breast feeding unless the expected benefit is thought to outweigh any possible risk and only on medical advice.



No studies on the effect on human fertility have been conducted.



4.7 Effects On Ability To Drive And Use Machines



No studies on the effects of DULCOLAX on the ability to drive and use machines have been performed.



However, patients should be advised that due to a vasovagal response (e.g. to abdominal spasm) they may experience dizziness and / or syncope. If patients experience abdominal spasm they should avoid potentially hazardous tasks such as driving or operating machinery.



4.8 Undesirable Effects



The most commonly reported adverse reactions during treatment are abdominal pain and diarrhoea.



Adverse events have been ranked under headings of frequency using the following convention: Very common (



Immune system disorders



Rare: anaphylactic reactions, angioedema, hypersensitivity.



Metabolism and nutrition disorders



Rare: dehydration.



Nervous system disorders



Uncommon: dizziness.



Rare: Syncope.



Dizziness and syncope occurring after taking bisacodyl appear to be consistent with a vasovagal response (e.g. to abdominal spasm, defaecation).



Gastrointestinal disorders



Uncommon: haematochezia (blood in stool), vomiting, abdominal discomfort, anorectal discomfort.



Common: abdominal cramps, abdominal pain, diarrhoea and nausea.



Rare: colitis.



4.9 Overdose



Symptoms



If high doses are taken watery stools (diarrhoea), abdominal cramps and a clinically significant loss of fluid, potassium and other electrolytes can occur.



Laxatives when taken in chronic overdose may cause chronic diarrhoea, abdominal pain, hypokalaemia, secondary hyperaldosteronism and renal calculi. Renal tubular damage, metabolic alkalosis and muscle weakness secondary to hypokalaemia have also been described in association with chronic laxative abuse.



Therapy



After ingestion of oral forms of DULCOLAX, absorption can be minimised or prevented by inducing vomiting or gastric lavage. Replacement of fluids and correction of electrolyte imbalance may be required. This is especially important in the elderly and the young. Administration of antispasmodics may be of value.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Bisacodyl is a locally acting laxative from the diphenylmethane derivatives group having a dual action. As a contact laxative, for which also antiresorptive hydragogue effects have been described, bisacodyl stimulates after hydrolysis in the large intestine, the mucosa of both the large intestine and of the rectum. Stimulation of the mucosa of the large intestine results in colonic peristalsis with promotion of accumulation of water, and consequently electrolytes, in the colonic lumen. This results in a stimulation of defecation, reduction of transit time and softening of the stool. Stimulation of the rectum causes increased motility and a feeling of rectal fullness. The rectal effect may help to restore the “call to stool” although its clinical relevance remains to be established.



5.2 Pharmacokinetic Properties



Following either oral or rectal administration, bisacodyl is rapidly hydrolyzed to the active principle bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), mainly by esterases of the enteric mucosa.



Administration as an enteric coated tablet was found to result in maximum BHPM plasma concentrations between 4 – 10 hours post administration whereas the laxative effect occurred between 6 – 12 hours post administration. In contrast, following the administration as a suppository, the laxative effect occurred on average approximately 20 minutes post administration; in some cases it occurred 45 minutes after administration. The maximum BHPM-plasma concentrations were achieved 0.5 – 3 hours following the administration as a suppository. Hence, the laxative effect of bisacodyl does not correlate with the plasma level of BHPM. Instead, BHPM acts locally in the lower part of the intestine and there is no relationship between the laxative effect and plasma levels of the active moiety. For this reason, bisacodyl coated tablets are formulated to be resistant to gastric and small intestinal juice. This results in a main release of the drug in the colon, which is the desired site of action.



After oral and rectal administration, only small amounts of the drug are absorbed and are almost completely conjugated in the intestinal wall and the liver to form the inactive BHPM glucuronide. The plasma elimination half-life of BHPM glucuronide was estimated to be approximately 16.5 hours. Following the administration of bisacodyl coated tablets, an average of 51.8% of the dose was recovered in the faeces as free BHPM and an average of 10.5% of the dose was recovered in the urine as BHPM glucuronide. Following the administration as a suppository, an average of 3.1% of the dose was recovered as BHPM glucuronide in the urine. Stool contained large amounts of BHPM (90% of the total excretion) in addition to small amounts of unchanged bisacodyl.



5.3 Preclinical Safety Data



There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Hard fat (Adeps solidus)



6.2 Incompatibilities



None stated.



6.3 Shelf Life



5 years



6.4 Special Precautions For Storage



Do not store above 25°C



In order to protect from light, keep the blister in the outer carton.



6.5 Nature And Contents Of Container



DULCOLAX 10 mg Suppositories are presented in aluminium foil blister strips coated with polyethylene.



Pack sizes of 6, 10, 12, 20, 50 and 200.



Not all pack sizes may be marketed.



6.6 Special Precautions For Disposal And Other Handling



None stated.



7. Marketing Authorisation Holder



Boehringer Ingelheim Limited,



Consumer Healthcare



Ellesfield Avenue,



Bracknell,



Berkshire,



RG12 8YS,



United Kingdom.



8. Marketing Authorisation Number(S)



PL 00015/0243



9. Date Of First Authorisation/Renewal Of The Authorisation



01 April 1999



10. Date Of Revision Of The Text



March 2011



11. LEGAL CATEGORY


Pharmacy only, P